Neurobo Pharmaceuticals Company Leadership
| NRBO Stock | USD 2.36 0.01 0.43% |
Neurobo Pharmaceuticals employs about 8 people. The company is managed by 7 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.14 employees per reported executive. Analysis of Neurobo Pharmaceuticals' management performance can provide insight into the firm performance.
Neurobo Pharmaceuticals' Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
| 2024-09-12 | St Co. Ltd Dong-A | Disposed 407 @ 3.75 | View | ||
| 2024-06-23 | St Co. Ltd Dong-A | Acquired 2544530 @ 3.13 | View |
Monitoring Neurobo Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Neurobo |
Neurobo Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Neurobo Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Neurobo will maintain a workforce of about 16 employees by December 2024.Neurobo Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.7435) % which means that it has lost $0.7435 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6076) %, meaning that it created substantial loss on money invested by shareholders. Neurobo Pharmaceuticals' management efficiency ratios could be used to measure how well Neurobo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -0.57. In addition to that, Return On Capital Employed is likely to drop to -0.99. As of the 28th of November 2024, Net Tangible Assets is likely to grow to about 17.6 M, while Total Assets are likely to drop about 18.4 M.As of the 28th of November 2024, Common Stock Shares Outstanding is likely to grow to about 5.3 M, while Net Loss is likely to drop (14.4 M).
Neurobo Pharmaceuticals Workforce Comparison
Neurobo Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 171. Neurobo Pharmaceuticals holds roughly 8.0 in number of employees claiming about 5% of equities under Health Care industry.
Neurobo Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neurobo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neurobo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Neurobo Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 1.0 | 2 | 2 | 6,361,325 | 11,874 |
| 2022-09-01 | 0.5 | 1 | 2 | 4,671 | 2,890,534 |
| 2019-12-01 | 1.4 | 7 | 5 | 9,722,612 | 0.00 |
| 2017-09-01 | 1.0 | 4 | 4 | 13,681 | 13,681 |
| 2017-03-01 | 4.5 | 9 | 2 | 211,585 | 211,834 |
| 2016-09-01 | 1.4483 | 42 | 29 | 2,991,760 | 502,908 |
Neurobo Pharmaceuticals Notable Stakeholders
A Neurobo Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Neurobo Pharmaceuticals often face trade-offs trying to please all of them. Neurobo Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Neurobo Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| HyungHeon Kim | President CEO | Profile | |
| Marshall Woodworth | Principal CFO | Profile | |
| PharmD BCPS | VP Operations | Profile | |
| Robert Homolka | Senior Operations | Profile | |
| Ben MD | CEO Pres | Profile | |
| Frank Kondrad | VP Devel | Profile | |
| MiKyung Kim | Chief Officer | Profile |
About Neurobo Pharmaceuticals Management Performance
The success or failure of an entity such as Neurobo Pharmaceuticals often depends on how effective the management is. Neurobo Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neurobo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neurobo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.55) | (0.57) | |
| Return On Capital Employed | (0.94) | (0.99) | |
| Return On Assets | (0.55) | (0.57) | |
| Return On Equity | (0.75) | (0.78) |
Neurobo Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Neurobo Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Neurobo Pharmaceuticals within its industry.Neurobo Pharmaceuticals Manpower Efficiency
Return on Neurobo Pharmaceuticals Manpower
| Revenue Per Employee | 875 | |
| Revenue Per Executive | 1000 | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 2.1M | |
| Working Capital Per Executive | 2.4M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.